XML 40 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Share-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Employees and Directors Stock Options The following table contains information concerning options granted under the existing equity incentive plan
   Three months ended June 30, 
   2023   2022 
  

Number of
options

   Weighted
average
exercise
price
   Number of
options
   Weighted
average
exercise
price
 
Outstanding at beginning of period   2,929,868   $5.84    2,399,622   $5.95 
Forfeited and expired   (14,375)  $6.82    (3,000)  $5.34 
Exercised   
-
   $
-
    (7,625)  $6.49 
Outstanding at end of period   2,915,493   $5.84    2,388,997   $5.95 
Exercisable at end of period   2,090,378   $5.59    1,728,623   $5.10 
                     
Non-vested at beginning of period   876,851   $6.48    722,749   $7.67 
Vested   (37,861)  $11.13    (59,375)  $(8.78)
Forfeited   (13,875)  $5.90    (3,000)  $(5.34)
Non-vested at the end of period   825,115   $6.27    660,374   $7.59 

 

   Six months ended June 30, 
   2023   2022 
  

Number of
options

   Weighted
average
exercise
price
   Number of
options
   Weighted
average
exercise
price
 
Outstanding at beginning of period   2,939,434   $5.85    2,142,547   $6.02 
Granted   -        $264,700   $5.48 
Forfeited and expired   (23,941)  $6.71    (3,000)  $5.34 
Exercised   -        $(15,250)  $6.49 
Outstanding at end of period   2,915,493   $5.84    2,388,997   $5.95 
Exercisable at end of period   2,090,378   $5.59    1,728,623   $5.10 
                     
Non vested at beginning of period   986,005   $6.46    529,082   $8.69 
Granted   -   $-    264,700   $5.48 
Forfeited and expired   (15,375)  $6.73    (3,000)  $5.34 
vested   (145,515)  $7.44    (130,408)  $7.82 
Outstanding at end of period   825,115   $6.27    660,374   $7.59 
Schedule of Exercise Prices and Remaining Contractual Life Set forth below is data regarding the range of exercise prices and remaining contractual life for all options outstanding on June 30, 2023
Exercise
price
   Number of
options outstanding
   Remaining
contractual
Life (in years)
   Intrinsic
Value of
Options
Outstanding
(in thousands)
   No. of options
exercisable
 
$2.69    649,883    1.92    
        -
    649,883 
$3.66    250,000    6.84    
-
    250,000 
$4.68    48,750    6.75    
-
    36,563 
$5.34    208,825    8.75    
-
    53,800 
$5.34    445,792    9.38    
-
    69,263 
$5.96    150,000    9.38    
-
    
-
 
$6.22    634,177    4.00    
-
    634,177 
$8.19    150,000    6.38    
-
    112,500 
$8.23    12,500    8.38    
-
    5,000 
$9.02    40,500    7.38    
-
    20,250 
$10.12    12,126    5.43    
-
    12,126 
$12.23    250,000    7.91    
-
    194,444 
$14.00    60,500    7.82    
-
    50,417 
$21.40    1,940    6.07    
-
    1,455 
$90.16    500    1.42    
-
    500 
      2,915,493         
-
    2,090,378 

 

Schedule of Restricted Stock Units The following table contains information concerning restricted stock units granted under the existing equity incentive plan
   Three months ended June 30, 
   2023   2022 
  

Number of
shares

   Weighted
average
grant date
fair value
   Number of
shares
   Weighted
average
grant date
fair value
 
Nonvested at beginning of period   114,329   $9.97    184,787   $10.02 
Vested   (3,438)  $10.28    (3,437)  $10.28 
Forfeited   (313)  $14.67    
-
   $
-
 
Nonvested at end of period   110,578   $9.95    181,350   $10.02 
   Six months ended June 30, 
   2023   2022 
   Number of
shares
   Weighted
average
grant date
fair value
   Number of
shares
   Weighted
average
grant date
fair value
 
Nonvested at beginning of period   157,560   $10.02    229,331   $10.08 
Vested   (46,544)  $10.15    (47,981)  $10.29 
Forfeited   (438)  $14.67    
-
   $
-
 
Nonvested at end of period   110,578   $9.95    181,350   $10.02 
Schedule of Share-Based Compensation Expenses Related to Grants Under the Equity Incentive Plan The following table summarizes share-based compensation expenses related to grants under the existing equity incentive plan included in the statements of operations
   Three months ended
June 30,
   Six months ended
June 30,
 
(in thousands)  2023   2022   2023   2022 
Research & development  $122   $119   $318   $509 
General & administrative   389    578    826    976 
Total  $511   $697   $1,144   $1,485